Welcome to our dedicated page for Agenus SEC filings (Ticker: AGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Agenus Inc. (NASDAQ: AGEN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a publicly traded immuno-oncology developer. As a filer under the Securities Exchange Act of 1934, Agenus uses Forms 8-K, 10-Q, 10-K and proxy materials to report financial results, clinical and corporate milestones, and shareholder actions related to its cancer immunotherapy programs.
Recent Form 8-K filings illustrate how these documents track material events. Agenus has furnished quarterly financial results for periods in 2025, reported on its annual meeting of stockholders and voting outcomes on director elections and equity plans, and described a promissory note agreement with a Zydus Lifesciences subsidiary tied to the planned sale of its Emeryville and Berkeley biologics manufacturing facilities. Other 8-Ks outline progress on the broader asset purchase, stock purchase and license agreements with Zydus, including updates on the Committee on Foreign Investment in the United States (CFIUS) review process.
For investors analyzing Agenus, periodic reports such as Forms 10-Q and 10-K (when available) are central to understanding the company’s financial condition, risk factors and research and development focus in immuno-oncology. These filings typically discuss the BOT+BAL clinical program, broader pipeline of antibody therapeutics, adoptive cell therapies and adjuvants, and the company’s development capabilities and collaborations.
On Stock Titan, each new Agenus filing is captured from EDGAR and paired with AI-powered summaries designed to highlight the most important points—such as key terms of financing arrangements, updates on the Zydus collaboration, or changes in capital structure. Users can also review Forms 4 and related ownership reports to monitor insider transactions in AGEN shares. This centralized view helps readers navigate complex SEC documents and quickly identify information relevant to Agenus’ immuno-oncology strategy, clinical progress and corporate governance.
ARMEN GARO H reported acquisition or exercise transactions in this Form 4 filing.
Agenus Inc. director and officer Garo H. Armen received a stock award of 4,829 shares of common stock as salary paid in stock for the pay period ending February 20, 2026, valued at $3.06 per share and fully vested on issuance, increasing his direct holdings to 325,541 shares.
He also reports indirect ownership of 31,298 shares held in his IRA accounts and 28,950 shares held through the Garo Armen 2020 2 Year AG GRAT and Pixie Partners, where he has only a partial pecuniary interest.
Agenus Inc. Chairman and CEO Garo H. Armen received 5,027 shares of common stock on February 6, 2026 as salary paid in stock instead of cash, at a reference price of $2.94 per share. These fully vested shares were issued under the Amended and Restated Agenus Inc. 2019 Equity Incentive plan and increased his directly held common stock to 320,712 shares.
In addition, the filing notes 31,298 shares held in Dr. Armen’s IRA accounts and 28,950 shares held through entities including the Garo Armen 2020 2 Year AG GRAT and Pixie Partners, where he has investment roles and a limited pecuniary interest.
Agenus Inc. director and Chairman/CEO Garo H. Armen reported receiving 4,562 shares of Agenus common stock on January 23, 2026. The shares were issued at $3.24 per share, which was the closing price of the stock on that date, and represent his net salary for the pay period ending January 23, 2026, paid in stock instead of cash under the company’s 2019 equity incentive plan. After this transaction, Dr. Armen directly beneficially owned 315,685 Agenus common shares, with additional indirect holdings reported through IRA accounts and a trust/general partnership structure described in the footnotes.
Zydus Lifesciences and its affiliates have disclosed a new 5.9% stake in Agenus Inc. common stock on Schedule 13D. Through Zynext Ventures USA LLC, they acquired 2,133,333 shares at $7.50 per share, for an aggregate purchase price of about $16.0 million on January 15, 2026, based on 36,141,682 shares outstanding including this issuance.
The share purchase is part of a broader strategic collaboration between Zydus and Agenus. Zydus may appoint either a board observer or a board member as long as it maintains significant ownership of Agenus stock. Alongside the equity investment, an affiliate of Zydus agreed to buy certain Agenus manufacturing operations, real estate, equipment and contracts for cash, and Zydus Lifesciences Ltd received an exclusive license to develop, manufacture and commercialize botensilimab and balstilimab in India and Sri Lanka in exchange for royalties on net sales.
Under the Securities Purchase Agreement, Agenus agreed to file a registration statement to register the resale of the 2,133,333 shares within 60 days of closing and to use commercially reasonable efforts to have it declared effective within specified SEC review timelines.
Agenus Inc. filed an initial ownership report for Principal Accounting Officer Austin Charette, detailing his equity position as of January 8, 2026. He directly beneficially owns 9,115 shares of Agenus common stock and a series of employee stock options (rights to buy common stock) with various exercise prices and expiration dates. These options include grants made under the Agenus Inc. 2019 Equity Incentive Plan (as amended), with vesting schedules that provide for one third of the underlying shares to vest on a specified anniversary date and the remaining shares to vest in equal quarterly installments thereafter, generally contingent on continued employment. The filing is informational and records Charette’s current direct holdings rather than new share purchases or sales.
Agenus Inc. has completed the sale of substantially all assets of its manufacturing operations, primarily run through Agenus West, to Zydus for cash consideration of $75.0 million, less certain reimbursable expenses and other closing payments, with the transaction closing on January 15, 2026. The disposition is treated as a significant business disposition, and Agenus has filed unaudited pro forma condensed consolidated financial statements as of September 30, 2025 and for earlier periods.
At the same time, a previously announced License Agreement with Zydus Lifesciences Limited became effective, granting Zydus an exclusive license in India and Sri Lanka to develop, manufacture, and commercialize products based on Agenus’ proprietary BOT/BAL cancer immunotherapy drug product. Agenus also closed a Securities Purchase Agreement with Zynext Ventures USA LLC, under which Zynext purchased 2,133,333 shares of Agenus common stock for approximately $16.0 million, or $7.50 per share, in an unregistered equity sale.
Agenus Inc. reported leadership changes in its finance function. Effective January 8, 2026, the Board appointed Chairman and Chief Executive Officer Dr. Garo Armen, age 72, to also serve as interim Chief Financial Officer and Principal Financial Officer. There were no new or modified compensation arrangements tied to this added role, and he continues to receive his base salary and any potential bonus payments in Agenus stock rather than cash.
Also effective January 8, 2026, the Board appointed Austin Charette, age 37, currently Senior Director of Financial Reporting and Compliance, as Principal Accounting Officer. He has been with Agenus since 2017 in various financial reporting and compliance roles, following prior experience at Deloitte & Touche LLP. The company states there are no new compensation arrangements or related-party relationships connected to either appointment.
Agenus Inc. Chairman and CEO Garo H. Armen, who also serves as a director, reported receiving 3,780 shares of Agenus common stock on January 9, 2026. According to the disclosure, at his request and with compensation committee approval, his salary for the pay period ending that date is being paid in stock instead of cash, with these shares fully vested on issuance and valued at the closing price of $3.91 per share on January 9, 2026.
After this stock-salary grant, Dr. Armen directly holds 311,123 shares of Agenus common stock. He also has indirect holdings, including 31,298 shares in IRA accounts and 28,950 shares held through the Garo Armen 2020 2 Year AG GRAT and Pixie Partners, where he is trustee or general partner and has a pecuniary interest in only a portion of certain shares.
Agenus Inc. entered into an amendment and release agreement with Ligand Pharmaceuticals related to a previously disclosed purchase and sale agreement and warrant. Under this amendment, Ligand agreed to release liens it holds on certain Agenus assets. In return, the exercise price of Ligand’s warrant was reduced from
AGENUS INC reported an insider equity transaction by its Chairman and Chief Executive Officer, Garo H. Armen, who is also a director. On December 26, 2025, Dr. Armen received 4,942 shares of common stock as payment of his salary for the pay period ending that day, instead of cash. These shares were issued under the Amended and Restated Agenus Inc. 2019 Equity Incentive plan and were fully vested on the date of issuance, at a reference price of $3.31 per share, which was the closing price of the common stock on that date.
Following this transaction, Dr. Armen beneficially owned 307,343 shares of Agenus common stock directly. He also held shares indirectly, including amounts in his IRA accounts and interests in entities such as the Garo Armen 2020 2 Year AG GRAT and Pixie Partners, where he has only a partial pecuniary interest.